⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Official Title: A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma

Study ID: NCT01166490

Interventions

ASG-5ME

Study Description

Brief Summary: This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and tolerability in patients with relapsed or refractory gastric adenocarcinoma.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States

University of California at San Francisco, San Francisco, California, United States

University of Chicago, Chicago, Illinois, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States

Texas Oncology - Tyler, Tyler, Texas, United States

Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States

Contact Details

Name: Nancy Whiting, PharmD, BCOP

Affiliation: Seagen Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: